|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.15 EUR | -1.21% |
|
+0.17% | -18.27% |
| 04-13 | RBC Capital Favors Diasorin Over bioMérieux |  |
| 04-10 | AlphaValue Urges Patience on bioMérieux, Maintains Buy Rating | |
Main competitors
| P/E (N) | Price to Book (N) | PEG (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | 19.85x | 2.31x | 0.53x | 2.41x | 9.52x | 13.87x | 1.24% | 12.53B | |
| -30.67x | -30.9x | 2.73x | 9.67x | -68.82x | -32.48x | -.--% | 11.95B | |
| 210.7x | 8.95x | -1.69x | 5.43x | 32.51x | 82.25x | -.--% | 6B | |
| 23.39x | - | 4.61x | 3.64x | 10.42x | 11.35x | - | 5.46B | |
| 21.24x | 3.74x | -2.64x | 7.28x | 16.73x | 18.33x | 2.63% | 5.22B | |
| 18.73x | 1.81x | 1.01x | 3.26x | 10.15x | 13.91x | 2.06% | 3.94B | |
| -26.87x | 4.25x | -0.15x | 4.68x | -30.49x | -22.55x | -.--% | 3.14B | |
| 17.15x | 2.11x | -4.54x | - | - | - | 3.46% | 2.85B | |
| 28.6x | 1.77x | -0.26x | 4.19x | 13.47x | 19.85x | 1.01% | 1.65B | |
| 33.15x | 1.43x | 2.23x | - | - | - | 2.9% | 1.51B | |
| 21.64x | 3.84x | 1.22x | 5.59x | 14.81x | 16.04x | 1.61% | 1.29B | |
| 32.62x | 1.48x | -0.59x | - | - | - | - | 1.21B | |
| 23.67x | 1x | 0.2x | - | - | - | 1.5% | 946M | |
| Average | 30.25x | 0.15x | 0.20x | 5.13x | 0.92x | 13.40x | 1.49% | 4.44B | |
| Weighted average by Cap. | 27.92x | -4.36x | 0.61x | 5.43x | -7.39x | 9.27x | 1.11% |
- Stock Market
- Equities
- BIM Stock
- Sector bioMérieux
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition